CO2021015054A2 - Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas - Google Patents

Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Info

Publication number
CO2021015054A2
CO2021015054A2 CONC2021/0015054A CO2021015054A CO2021015054A2 CO 2021015054 A2 CO2021015054 A2 CO 2021015054A2 CO 2021015054 A CO2021015054 A CO 2021015054A CO 2021015054 A2 CO2021015054 A2 CO 2021015054A2
Authority
CO
Colombia
Prior art keywords
solid
improved performance
plasma concentrations
achieve therapeutic
therapeutic plasma
Prior art date
Application number
CONC2021/0015054A
Other languages
English (en)
Spanish (es)
Inventor
Robert J Garmise
Jaquan Kalani Levons
Jay Poorna Reddy
Kevin J Stefanski
Vrushali M Waknis
Theresa M Ziemba
Ajay Saxena
Srikanth Koravady Sridhar
Gajendra Singh Chowan
Sharmistha Pal
Shabeerali Pattasseri
Roopa Narasimhamurthy
Narayan Swamy Panduranga
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CO2021015054A2 publication Critical patent/CO2021015054A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CONC2021/0015054A 2019-04-11 2021-11-08 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas CO2021015054A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962832606P 2019-04-11 2019-04-11
PCT/US2020/027677 WO2020210629A1 (en) 2019-04-11 2020-04-10 Enhanced performance of amorphous solid and solubilized formulations for achieving therapeutic plasma concentrations

Publications (1)

Publication Number Publication Date
CO2021015054A2 true CO2021015054A2 (es) 2021-11-19

Family

ID=70465560

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0015054A CO2021015054A2 (es) 2019-04-11 2021-11-08 Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas

Country Status (18)

Country Link
US (2) US12509461B2 (https=)
EP (1) EP3953355A1 (https=)
JP (2) JP2022526656A (https=)
KR (1) KR20210151183A (https=)
CN (1) CN113924300A (https=)
AR (1) AR118650A1 (https=)
AU (2) AU2020271103B2 (https=)
BR (1) BR112021020257A2 (https=)
CA (1) CA3132530A1 (https=)
CL (1) CL2021002627A1 (https=)
CO (1) CO2021015054A2 (https=)
EA (1) EA202192753A1 (https=)
IL (1) IL287103A (https=)
MX (2) MX2021012288A (https=)
PE (1) PE20212367A1 (https=)
SG (1) SG11202111131VA (https=)
TW (1) TW202104228A (https=)
WO (1) WO2020210629A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3212644A1 (en) 2021-03-09 2022-09-15 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5- dioxo-14-(trifluoromethyl)-32h-6-aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)- dibenzenaheptaphane-74-carboxamide
IL310894A (en) 2021-09-17 2024-04-01 Bristol Myers Squibb Co Milovacian for the prevention and treatment of thromboembolic disorders
MA71692A (fr) 2022-08-01 2025-05-30 Bristol-Myers Squibb Company Utilisation de milvexian pour le traitement ou la prévention d'un accident vasculaire cérébral ischémique
KR20250136432A (ko) 2023-02-06 2025-09-16 브리스톨-마이어스 스큅 컴퍼니 밀벡시안 제약 조성물
WO2025099743A1 (en) * 2023-11-07 2025-05-15 Dr. Reddy’S Laboratories Limited Process for preparation of milvexian and solid-state forms thereof
WO2025126240A1 (en) * 2023-12-12 2025-06-19 Dr. Reddy's Laboratories Limited Pharmaceutical compositions and use thereof
WO2025220042A1 (en) * 2024-04-18 2025-10-23 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising asundexian and use thereof
WO2025224678A1 (en) 2024-04-25 2025-10-30 Assia Chemical Industries Ltd. Solid state forms of milvexian and process for preparation thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83812B (en) 1985-11-27 1988-03-15 Syntex Inc Process for preparing amorphous benzimidazole derivatives
ES2287971T3 (es) 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
CN1402629A (zh) * 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
CA2737400C (en) * 2008-10-07 2016-11-22 Astrazeneca Uk Limited Pharmaceutical formulation 514
WO2010102245A1 (en) 2009-03-05 2010-09-10 Upsher-Smith Laboratories, Inc. Solid dispersion comprising resveratrol
MY172424A (en) * 2009-04-03 2019-11-25 Hoffmann La Roche Propane- i-sulfonic acid {3- (4-chloro-phenyl)-1h-pyrrolo [2, 3-b] pyridine-3-carconyl] -2, 4-difluoro-phenyl} -amide compositions and uses thereof
SG10201908467RA (en) 2014-01-31 2019-10-30 Bristol Myers Squibb Co Macrocycles with hetrocyclic p2' groups as factor xia inhibitors
PT107568B (pt) 2014-03-31 2018-11-05 Hovione Farm S A Processo de secagem por atomização para a produção de pós com propriedades melhoradas.
NO2721243T3 (https=) 2014-10-01 2018-10-20
US9453018B2 (en) * 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
JP6203702B2 (ja) 2014-11-18 2017-09-27 信越化学工業株式会社 ヒプロメロース酢酸エステルコハク酸エステルを用いたスプレードライ用溶液及び固体分散体の製造方法
ES2791319T3 (es) 2016-04-22 2020-11-03 Astrazeneca Ab Inhibidores de MCL1 macrocíclicos para tratar el cáncer

Also Published As

Publication number Publication date
AU2020271103A1 (en) 2021-12-02
AR118650A1 (es) 2021-10-20
WO2020210629A1 (en) 2020-10-15
EA202192753A1 (ru) 2022-01-11
BR112021020257A2 (pt) 2021-12-07
TW202104228A (zh) 2021-02-01
AU2020271103B2 (en) 2026-01-08
MX2021012288A (es) 2021-11-12
IL287103A (en) 2021-12-01
AU2025279715A1 (en) 2026-01-15
MX2025011559A (es) 2025-11-03
JP2025131625A (ja) 2025-09-09
CN113924300A (zh) 2022-01-11
CA3132530A1 (en) 2020-10-15
US20260042761A1 (en) 2026-02-12
US20220144835A1 (en) 2022-05-12
CL2021002627A1 (es) 2022-05-06
EP3953355A1 (en) 2022-02-16
US12509461B2 (en) 2025-12-30
JP2022526656A (ja) 2022-05-25
SG11202111131VA (en) 2021-11-29
PE20212367A1 (es) 2021-12-21
KR20210151183A (ko) 2021-12-13

Similar Documents

Publication Publication Date Title
CO2021015054A2 (es) Rendimiento mejorado de formulaciones sólidas y solubilizadas amorfas para lograr concentraciones de plasma terapéuticas
MX2022001828A (es) Formas cristalinas de moduladores del regulador de conductancia transmembrana de la fibrosis quistica (cftr).
JOP20180123A1 (ar) مركبات علاجية مفيدة للوقاية من أو علاج الإصابة بفيروس نقص المناعة البشرية
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CY1119488T1 (el) Παραγων για θεραπεια ή/και αποτροπη διαταραχης υπνου
CY1119175T1 (el) Καινοτομες τρικυκλικες ενωσεις
UY35362A (es) Compuestos terapéuticos
MX2023002233A (es) Compuestos fosfolipidos y usos de estos.
MX376833B (es) Oxiesteroles y metodos de uso de los mismos.
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CO2018007669A2 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza
MX382122B (es) Oxiesteroles y metodos de uso de los mismos.
CU24525B1 (es) Derivado de quinoleína para tratar y prevenir infecciones virales
CO2021007453A2 (es) Conjugados de insulina
MX2020009530A (es) Inhibidores de la o-glicoproteína-2-acetamido-2-desoxi-3-dglicopir anosidasa.
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
AR105478A1 (es) Grados líquidos y sólidos fundibles de peróxidos protegidos por quemadura
MX2017010623A (es) Derivados de quinoleina para usarse en el tratamiento o prevencion de una infeccion viral.
DK4514473T3 (da) Heterocykliske forbindelser som modulatorer af bcl6 som ligand-styrede nedbrydningsmidler
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
CU20200100A7 (es) Compuestos 3-ciano n-sustituidos de hidrotienopiridina útiles para prevenir y tratar las infecciones virales, especialmente dengue, y composiciones farmacéuticas que los contienen
MX2021005234A (es) Compuestos para el tratamiento de la infeccion por arenavirus.
AR109407A1 (es) Compuesto de 1-acetil-3-fenilurea y su uso
AR109409A1 (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso
AR106375A1 (es) Formulaciones para activar mosquitos